WO2014125410A1 - Dérivés hétérocycliques n-substitués à titre d'inhibiteurs de kinases - Google Patents

Dérivés hétérocycliques n-substitués à titre d'inhibiteurs de kinases Download PDF

Info

Publication number
WO2014125410A1
WO2014125410A1 PCT/IB2014/058894 IB2014058894W WO2014125410A1 WO 2014125410 A1 WO2014125410 A1 WO 2014125410A1 IB 2014058894 W IB2014058894 W IB 2014058894W WO 2014125410 A1 WO2014125410 A1 WO 2014125410A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
amino
pyrazin
carbonyl
morpholine
Prior art date
Application number
PCT/IB2014/058894
Other languages
English (en)
Inventor
Anima BORUAH
Subramanya Hosahalli
Sunil Kumar Panigrahi
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Publication of WO2014125410A1 publication Critical patent/WO2014125410A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to compounds useful for the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder associated where there is an advantage in inhibiting kinase enzyme activity, and more particularly Bruton's tyrosine kinase (Btk).
  • Btk Bruton's tyrosine kinase
  • the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of diseases or disorder associated with Btk.
  • Protein Kinase enzymes are known to be the key regulators of cell activities that constitute one of the largest and most functionally diverse gene families. Protein kinases participate in the signalling events that control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these protein kinases fall into several groups; those which preferentially phosphorylate serine and/or threonine residues and those which preferentially phosphorylate tyrosine residues.
  • diseases and/or disorders are associated with aberrant, abnormal or deregulated activity of one or more kinases and subsequently in their pathways.
  • diseases and/or disorders include, but are not limited to cancers, allergic diseases and/or disorders, autoimmune diseases and/or disorders, inflammatory diseases and/or disorder and/or conditions associated with inflammation and pain, proliferative diseases, hematopoietic disorders, hematological malignancies, bone disorders, fibrosis diseases and/or disorders, metabolic disorders, muscle diseases and/or disorders respiratory diseases and/or disorders, pulmonary disorders, genetic developmental diseases, neurological and neurodegenerative diseases/or disorders, chronic inflammatory demyelinating neuropathies, cardiovascular, vascular or heart diseases and/or disorders, ophthalmic/ocular diseases and/or disorders, wound repair, infection and viral diseases.
  • Bruton's Tyrosine Kinase (Btk) is a member of the Tec family of tyrosine kinases, and is a critical regulator of early B-Cell development as well as mature B-cell activation, signaling and survival (Kurosaki, Curr Op Imm, 2000, 276-281; Schaeffer and Schwartzberg, Curr Op Imm 2000, 282-288.
  • Btk also plays role in a number of other hematopoietic cell signalling pathways, e.g., Toll like receptor (TLR) and cytokine receptor-mediated TNF-a production in macrophages, IgE receptor signalling in Mast cells, inhibition of Fas/APO-1 apoptotic signalling in B-lineage lymphoid cells, and collagen-stimulated platelet aggregation (C. A. Jeffries, et al., (2003), Journal of Biological Chemistry 278:26258-26264; N. J. Horwood, et al., (2003), The Journal of Experimental Medicine 197: 1603-1611.
  • TLR Toll like receptor
  • cytokine receptor-mediated TNF-a production in macrophages IgE receptor signalling in Mast cells
  • Fas/APO-1 apoptotic signalling in B-lineage lymphoid cells
  • collagen-stimulated platelet aggregation C. A. Jeffries, et al.,
  • B-cell signaling through the B-cell receptor leads to a wide range of biological outputs, which in turn depend on the developmental stage of the B-cell.
  • Btk is recruited to the cell membrane and phosphorylated in the activation loop by src family kinases. Subsequent Btk auto-phosphorylation stabilizes the active confirmation and fully activates Btk kinase activity.
  • Btk phosphorylates phospho lipase (PLCy), initiating calcium mobilization and generating diacylglycerol (DAG) as secondary signals, eventually leading to transcriptional activation and amplification of BCR stimulation (Satterthwaite AB, Witte ON (2000), Immunol Rev 175: 120-127; Khan WN (2001), Immunol Res 23: 147-156.
  • PLCy phospholipase
  • DAG diacylglycerol
  • Aberrant BCR mediated signalling can cause deregulated B-cell proliferation and/or formation of pathogenic antibodies leading to multiple autoimmune and/or inflammatory diseases.
  • inhibitors of Btk may be useful as inhibitors of B-cell mediated pathogenic activity.
  • Btk-deficient mouse models e.g. in standard murine preclinical models of Systemic Lupus Erythematosus (SLE), Btk deficiency has been shown to result in a marked reduction of disease progression (Minoru Satoh et al (2003) Int. Immunol. 15 (9): 1117-1124.
  • Btk deficient mice are also resistant to developing collagen- induced arthritis and are less susceptible to Staphylococcus- induced arthritis (Svensson et al (1998) Clin Exp Immunol. March; 111(3): 521-526.
  • Btk activity appears to be useful for the treatment of autoimmune and/or inflammatory diseases such as SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma.
  • ITP idiopathic thrombocytopenic purpura
  • Btk has been reported to play a role in apoptosis, thus inhibition of Btk activity is useful for the treatment of B-cell lymphoma and leukaemia. They may also be useful as part of other therapeutic regimens for the treatment of disorders, alone or in combination with protein kinase compounds well known by the one skilled in the art.
  • novel N-substituted heterocyclic derivatives according to the present invention may possess inhibitory activity of one or more protein kinases including Btk and are, therefore, expected to be useful in the treatment of kinase-associated diseases or disorders.
  • the present invention relates to N-substituted heterocyclic derivatives of formula (I) which are useful as kinase inhibitors.
  • the present invention relates to the compound of formula (I)
  • the dotted line [— ] represents a single or a double bond
  • Ri is selected from alkyl, cycloalkyl, -N(R a )Rb, optionally substituted aryl, arylalkyl and optionally substituted heterocyclyl; wherein the optional substituent at each occurrence is independently selected from one or more R$;
  • R 2 is selected fro
  • R 3 is selected from optionally substituted aryl and heterocyclyl; wherein the optional substituent is selected from -N(R 6 )R7 and -C(0)N(R 6 )R 7 ;
  • R4 and R5 are independently selected from hydrogen and alkyl; R 6 and R 7 taken together with the nitrogen atom to which they are attached to form an optionally substituted 4-6 membered heterocyclyl ring containing 0-2 heteroatoms independently selected from N and O; wherein the optional substituent is alkyl;
  • Rs is selected from alkyl, alkoxy, halogen, haloalkyl, and -S(0) 2 alkyl;
  • R a and R b are independently selected from hydrogen and optionally substituted aryl; wherein the optional substituents are selected from alkyl, halogen, alkoxy and haloalkyl; and
  • 'n' is an integer selected from 1 and 2.
  • Embodiments of the present invention provide N-substituted heterocyclic derivatives of formula (I) which are useful as k
  • the dotted line [— ] represents a single or a double bond
  • Ri is selected from alkyl, cycloalkyl, -N(R a )Rt > , optionally substituted aryl, arylalkyl and optionally substituted heterocyclyl; wherein the optional substituent at each occurrence is independently selected from one or more R$;
  • R 2 is selected from
  • R 3 is selected from optionally substituted aryl and heterocyclyl; wherein the optional substituent is selected from -N(R 6 )R7 and -C(0)N(R 6 )R 7 ;
  • R4 and R5 are independently selected from hydrogen and alkyl
  • R 6 and R 7 taken together with the nitrogen atom to which they are attached to form an optionally substituted 4-6 membered heterocyclyl ring containing 0-2 heteroatoms independently selected from N and O; wherein the optional substituent is alkyl;
  • Rs is selected from alkyl, alkoxy, halogen, haloalkyl, and -S(0)2alkyl;
  • R a and R b are independently selected from hydrogen and optionally substituted aryl; wherein the optional substituents are selected from alkyl, halogen, alkoxy and haloalkyl; and
  • 'n' is an integer selected from 1 and 2.
  • Ri is alkyl, cycloalkyl and arylalkyl; in particular alkyl is methyl and isopropyl; cycloalkyl is cyclopropyl and arylalkyl is benzyl.
  • R a and R are selected from hydrogen and optionally substituted aryl; in particular aryl is phenyl.
  • R 3 is optionally substituted aryl; in particular aryl is phenyl.
  • R 3 is heterocyclyl; in particular heterocyclyl is pyridin-3-yl or pyridin-4-yl.
  • R 4 is hydrogen and R 5 is alkyl; in particular alkyl is methyl.
  • the compound of formula (I) is a compound of formula (la)
  • the compound of formula (I) is a compound of formula (lb)
  • the compound of formula (I) is a compound of formula (Ic)
  • Ri is methyl, isopropyl, cyclopropyl and optionally substituted phenyl; wherein optional substituent is alkyl; in particular alkyl is methyl and i-butyl.
  • the compound of formula (I) is a compound of formula (Id)
  • the compound of formula (I) is selected from the group consisting of Compd
  • the definition of "compounds of formula (I)” inherently includes all stereoisomers of the compound of formula (I) either as pure stereoisomer or as a mixture of two or more stereoisomers.
  • stereoisomers include enantiomers, diasteroisomers, racemates, cis-isomers, trans-isomers and mixture thereof.
  • the absolute configuration at an asymmetric atom is specified by either R or S.
  • Resolved compounds whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e.
  • the compounds and pharmaceutically compositions of the present invention are used in the treatment and/or prevention of diseases and/or disorders in which aberrant, abnormal or deregulated activity of Bruton's tyrosine kinase (Btk) contribute to the pathology and/or symptomology of diseases and/or disorders associated with Btk.
  • Btk Bruton's tyrosine kinase
  • the compounds of formula (I) are useful as medicament in treatment of diseases and/or disorders associated with Btk, which includes but are not limited to cancer, autoimmune and inflammatory disorders such as multiple sclerosis and rheumatoid arthritis.
  • Btk include, but are not limited to allergic disorders and/or autoimmune and/or inflammatory diseases and/or conditions associated with inflammation and pain, cancers, proliferative diseases, hematopoietic disorders, hematological malignancies, bone disorders, fibrosis diseases and/or disorders, metabolic disorders, muscle diseases and/or disorders respiratory diseases and/or disorders, pulmonary disorders, genetic developmental diseases, neurological and neurodegenerative diseases/or disorders, chronic inflammatory demyelinating neuropathies, cardiovascular, vascular or heart diseases and/or disorders, ophthalmic/ocular diseases and/or disorders, wound repair, infection and viral diseases.
  • the compounds according to the present invention possess potential of providing cancer cell growth inhibiting effects and are effective in treating cancers, autoimmune and inflammatory diseases; in particular cancer includes all types of solid cancers and malignant lymphomas but not limited to leukaemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain tumour & etc; and particularly the compounds according to the present invention are used in the treatment of autoimmune and/or inflammatory diseases and/or conditions associated with inflammation and pain include, but are not limited to acid reflux, heart burn, acne, allergies and allergen sensitivities, bronchitis, carditis, celiac disease, chronic pain, cirrhosis, colitis, dementia, dermatitis, diabetes, dry eyes, edema, emphysema, eczema, fibromyalgia, gastroenteritis, gingivitis, heart disease, hepatitis, high blood pressure,
  • Alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms; in particular alkyl is Q-Qo alkyl group which may have 1 to 10 (inclusive) carbon atoms in it; in more particular alkyl is Ci-C 6 alkyl group which may have 1 to 6 (inclusive) carbon atoms in it and in more preferred particular alkyl is C ⁇ - C 4 alkyl group which may have 1 to 4 (inclusive) carbon atoms in it.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert -butyl, isopentyl, neopentyl, and isohexyl.
  • An alkyl group can be unsubstituted or substituted with one or more suitable groups.
  • Alkoxy refers to the group alkyl-O- or -O-alkyl, wherein alkyl group is as defined above.
  • Exemplary Q-Qo alkyl group containing alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, zso-propoxy, n-butoxy and i-butoxy.
  • An alkoxy group can be unsubstituted or substituted with one or more suitable groups.
  • Halogen or "halo” includes fluorine, chlorine, bromine or iodine.
  • Haloalkyl refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with - F, -CI, -Br or -I.
  • Representative examples of an haloalkyl group include, but are not limited to -CH 2 F, -CC1 3 , -CF 3 , -CH 2 C1, -CH 2 CH 2 Br, - CH 2 CH 2 I, -CH 2 CH 2 CH 2 F, -CH 2 CH 2 CH 2 C1, -CH 2 CH 2 CH 2 CH 2 Br, -CH 2 CH 2 CH 2 CH 2 I, - CH 2 CH 2 CH 2 CH 2 CH 2 Br, -CH 2 CH 2 CH 2 CH 2 CH 2 I, -CH 2 CH(Br)CH 3 , -CH 2 CH(C1)CH 2 CH 3 , and - CH(F)CH 2 CH 3 .
  • Cycloalkyl refers to a non-aromatic, saturated, monocyclic, bicyclic or polycyclic hydrocarbon ring system.
  • Representative examples of a cycloalkyl include, but are not limited to cyclopropyl, cyclopentyl, cycloheptyl and cyclooctyl.
  • a cycloalkyl can be unsubstituted or substituted with one or more suitable groups.
  • Aryl refers to an optionally substituted monocylic, bicyclic or polycyclic aromatic hydrocarbon ring system of about 6 to 14 carbon atoms.
  • Examples of a C 6 -Ci 4 aryl group include, but are not limited to phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl and acenaphthyl.
  • Aryl group can be unsubstituted or substituted with one or more suitable groups.
  • Arylalkyl refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atom has been replaced with an aryl group as defined above.
  • arylalkyl group include, but are not limited to benzyl, benzhydryl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl.
  • An arylalkyl group can be unsubstituted or substituted with one or more suitable groups.
  • Heterocyclyl includes the definitions of "heterocycloalkyl” and “heteroaryl”.
  • the term “Heterocycloalkyl” refers to a non-aromatic, saturated or partially saturated, monocyclic or polycyclic ring system of 3 to 10 member having at least one heteroatom or heterogroup selected from O, N, S, S(O), S(0) 2 , NH and C(O).
  • Exemplary heterocycloalkyl groups include piperdinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,3-dioxolanyl, 1,4- dioxanyl and the like.
  • a heterocycloalkyl group can be unsubstituted or substituted with one or more suitable groups.
  • Heteroaryl refers to an unsaturated, monocyclic, bicyclic, or polycyclic aromatic ring system containing at least one heteroatom selected from oxygen, sulphur and nitrogen.
  • C5-C10 heteroaryl groups include furan, thiophene, indole, azaindole, oxazole, thiazole, thiadiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4- triazole, l-methyl-l,2,4-triazole, IH-tetrazole, 1-methyltetrazole, benzoxazole, benzothiazole, benzofuran, benzisoxazole, benzimidazole, N-methylbenzimidazole, aza
  • Bicyclic heteroaryl groups include those where a phenyl, pyridine, pyrimidine or pyridazine ring is fused to a 5 or 6-membered monocyclic heterocyclyl ring having one or two nitrogen atoms in the ring, one nitrogen atom together with either one oxygen or one sulfur atom in the ring, or one O or S ring atom.
  • a heteroaryl group can be unsubstituted or substituted with one or more suitable groups.
  • Hetero atom refers to a sulfur, nitrogen or oxygen atom.
  • suitable groups
  • “Comprise” or “Comprising” is generally used in the sense of include, that is to say permitting the presence of one or more features or components.
  • “Pharmaceutically acceptable salt” or “pharmaceutically acceptable derivatives” is taken to mean an active ingredient, which comprises a compound of the formula (I) in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
  • the pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
  • treat encompass either or both responsive and prophylaxis measures, e.g., measures designed to inhibit or delay the onset of the disease or disorder, achieve a full or partial reduction of the symptoms or disease state, and/or to alleviate, ameliorate, lessen, or cure the disease or disorder and/or its symptoms.
  • responsive and prophylaxis measures e.g., measures designed to inhibit or delay the onset of the disease or disorder, achieve a full or partial reduction of the symptoms or disease state, and/or to alleviate, ameliorate, lessen, or cure the disease or disorder and/or its symptoms.
  • treat include, but are not limited to, prophylactic and/or therapeutic treatments.
  • the terms "subject” or “patient” are well-recognized in the art, and, are used interchangeably herein to refer to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human.
  • the subject is a subject in need of treatment or a subject with a disease or disorder.
  • the subject can be a normal subject.
  • the term does not denote a particular age or sex. Thus, adult and newborn subjects, whether male or female, are intended to be covered.
  • terapéuticaally effective amount refers to a sufficient amount of a compound or a composition being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • “Pharmaceutically acceptable” means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
  • Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods.
  • Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).
  • a therapeutically effective amount of a compound of the formula (I) and of the other active ingredient depends on a number of factors, including, for example, the age and weight of the animal, the precise disease condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet.
  • an effective amount of a compound is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to lOmg/kg of body weight per day.
  • the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same.
  • An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound per se.
  • the present invention relates to a process for preparing N-substituted heterocyclic derivatives of formula (I).
  • An embodiment of the present invention provides the compounds according to formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimization procedures. The intermediates or compounds synthesized herein may be used in the further step with isolating or without isolating. Moreover, by utilizing the procedures described in detail, one of ordinary skill in the art can prepare additional compounds of the present invention claimed herein. All temperatures are in degrees Celsius (°C) unless otherwise noted.
  • the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
  • Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2 H ("D"), 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 32 P, 33 P, 35 S, 18 F, 36 C1, 123 I and 125 I.
  • Isotopically labeled compounds of the present inventions can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • ACN acetonitrile
  • AcCl AcCl chloride
  • atm atmosphere
  • Brine solution saturated Sodium chloride solution
  • bs broad singlet
  • CH 3 COOK Potassium acetate
  • CS 2 CO 3 Carbonate
  • °C degree Celsius
  • DMF N,N-dimethylformamide
  • DMSO Dimethyl sulfoxide
  • DMAP 4-Dimethylaminopyridine
  • DME diimethoxyethane
  • DMA Dimethyl amine
  • DIPEA/DIEA N,N- Diisopropylethylamine
  • Et 2 0 diethyl ether
  • CH 2 C1 2 /DCM diichloro methane
  • CDCI 3 deuteriated chloroform
  • d dublet
  • dd doublet of dublet
  • EDCI.HC1 l-(3-Dimethylaminopropyl)-3-car
  • Another embodiment of the present invention provides methods useful for making the compounds of formula (I) are set forth in the examples below and generalized in below scheme.
  • One of skill in the art will recognize that the below scheme can be adapted to produce the compounds of formula (I) and pharmaceutically accepted salts of compounds of formula (I) according to the present invention. Wherein all symbols/variables are as defined earlier unless otherwise stated. The process is represented herein by below scheme.
  • Bromo compound of formula 1.0 and Bis(pinacolato)diboron can undergo Pd-catalysed reaction with suitable Pd-catalyst such as Pd(PPh 3 ) 4 , Pd(dppf)Cl 2.
  • DCM, Pd 2 (dba) 3> Pd(OAc) 2 and the like in presence of a suitable base such as TEA, DIPEA, Na 2 C0 3> K 2 C0 3> Cs 2 C0 3 and the like and suitable organic solvents such as THF, ACN, DMF, DMA and DMSO at about 70°C to 110°C for about 2 to 8h to give the compound of formula of 1.1, which can further reacted with acid chlorides in presence of suitable bases such as NaH, TEA, DIPEA, Na 2 C0 3> K 2 C0 3> Cs 2 C0 3 and the like, in suitable polar solvents such as THF, ACN, DMF, DMA and DMSO at about RT to 80°C
  • Substituted pyrizinone derivatives of compound of formula 1.3 and appropriate amines are reacted in presence of suitable bases such as TEA, DIPEA, NaH, NaO l Bu and the like, in suitable organic solvents (such as DMF, ACN, THF, Dioxane, DMA) at about 100°C to 110°C for about 6 to 16 h to get the compound of formula 1.4.
  • suitable bases such as TEA, DIPEA, NaH, NaO l Bu and the like
  • suitable organic solvents such as DMF, ACN, THF, Dioxane, DMA
  • Pd-catalyzed reaction with formula 1.1 to provide formula 1.5.
  • This coupling reaction can be carried out in suitable Pd-catalyst such as Pd(PPh 3 ) 4 , Pd(dppf)Cl 2.
  • This coupling reaction can be carried out in suitable Pd-catalyst such as Pd(PPh 3 ) 4 , Pd(dppf)Cl 2 .DCM, Pd 2 (dba) 3 , Pd(OAc) 2 and the like, in presence of suitable bases such as Na 2 C0 3> K 2 C0 3> Cs 2 C0 3 and the like, and their molar solutions in suitable solvents such as DMF, THF, ACN, Dioxane and the like, at a temperature of about 20°C to 100°C for about 6- 24 h to get the compound of formula 1.8.
  • suitable Pd-catalyst such as Pd(PPh 3 ) 4 , Pd(dppf)Cl 2 .DCM, Pd 2 (dba) 3 , Pd(OAc) 2 and the like
  • suitable bases such as Na 2 C0 3> K 2 C0 3> Cs 2 C0 3 and the like
  • suitable solvents such as DMF, THF
  • Method-A Conversion of compound of formula- 1.5 to formula I (Amide formation) can be carried out by the similar method described in scheme-a.
  • Method-B The acid-amine coupling of compound of formula 1.5 was carried out by a conventional amide bond formation method by using a suitable coupling reagents such as benzotriazole-containing coupling reagents such as 1-hydroxybenzotriazole (HOBt) benzotriazole-l-yloxytris (dimethylamino)phosphoniumhexafluorophosphate and 2-(lH- benzotriazol-l-yl)-l, l,3,3-tetra methyluroniumhexafluoro phosphate or an azabenzotriazole- containing reagents such as 0-(7-azabenzotriazole-l-yl)-N or dicarboimides containing reagents such as l-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, dicyclohexylcarbodiimide, HATU, and the like, in a suitable solvent such as D
  • Method-C Compound of formula 1.5 treated with substituted aryl isocyanates in presence of suitable bases such as TEA, DIPEA, and the like, in suitable solvents such as THF, DCM at a temperature of about 0-35°C for about 2-12h to provide compound of formula I.
  • suitable bases such as TEA, DIPEA, and the like
  • suitable solvents such as THF, DCM
  • the microwave chemistry was performed on a CEM Explorer.
  • Step-(i) Synthesis of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indoline:
  • Step-(v) Synthesis of (4-((6-(indolin-4-yl)imidazo[l,2-a]pyrazin-8-yl)amino)phenyl) (morpholino)methanone:
  • step-(iv) of Intermediate- 10 and 11 The process of this step was adopted from step-(iv) of Intermediate- 10 and 11.
  • the desired compound obtained as an off white solid (0.220g, crude).
  • the obtained crude was used in the next step without analytical data.
  • Example-Ill Synthesis of N-(3,4-dimethylphenyl)-4-(4-methyl-6-((4-(morpholine-4-carbonyl) phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)indoline-l-carboxamide (Compound-23):
  • Example-IV Synthesis of 5-(l-(4-(tert-butyl)benzoyl)-lH-indol-4-yl)-l-methyl-3-((3-(4-methyl piperazin-l-yl) phenyl) amino) pyrazin-2(lH)-one (Compound-32):
  • Step-(v) Synthesis of 5-(l-(4-(tert-butyl)benzoyl)-lH-indol-4-yl)-l-methyl-3-((4-(4-methyl piperazin-l-yl)phenyl)amino)pyrazin-2(lH)-one:
  • Example-V Synthesis of 5-(l-acetylindolin-5-yl)- l-methyl-3-((4-(morpholine-4-carbonyl) phenyl)amino)pyrazin-2( lH)-one (Compound-33)
  • step-(iv) of compound-32 The process of this step was adopted from step-(iv) of compound-32.
  • Example- VI Synthesis of (4-((6-( l-(4-(tert-butyl)benzoyl)- lH-indol-4-yl)imidazo[ l,2- a]pyrazin-8-yl)amino)phenyl)(morpholino)methanone (Compound-34):
  • K 2 C0 3 95 mg, 0.684 mmol
  • tert-butyl benzoylchloride 67 mg, 0.342 mmol
  • Example-VI with appropriate variations in reactants, quantities of reagents and reaction conditions.
  • the physiochemical characteristics of the compounds are summarized herein below table.
  • Example- VII Synthesis of l-(4-(8-((4-(morpholine-4-carbonyl)phenyl)amino)imidazo[l,2- a]pyrazin-6-yl)indolin-l-yl)-2-phenylethanone (Compound-41):
  • Example- VIII Synthesis of (4-((6-(l-(4-(tert-butyl)benzoyl)indolin-5-yl)imidazo[l,2-a]pyrazin- 8-yl)amino)phenyl)(morpholino)methanone (Compound-49):
  • Example-X Synthesis of l-(5-(8-((4-(morpholine-4-carbonyl)phenyl)amino)imidazo[l,2-a] pyrazi ydroquinolin-l(2H)-yl)ethanone (Compound-54):
  • BTK TR-FRET kinase assay measures the phosphorylation of Ulight fluorescence acceptor labelled substrate by full length human recombinant BTK enzyme and the detection using Eu-labeled antiphosphotyrosine antibody. The binding of antibody to the phosphorylated tyrosine brings Eu closer to Ulight label. Due to the proximity, Eu excited at 340 nm, can transfer energy to Ulight label which emits at 665 nm.
  • TR-FRET assays are usually done as ratiometric measurements. The output signal is measured as the ratio of 665 nm emission of Ulight to 615 nm emission of Eu and it is proportional to the level of Ulight peptide phosphorylation.
  • test compounds at 20 mM DMSO are prepared. Compounds are serially diluted in 384-well pplypropylene plates. Diluted compounds are incubated with 5 ng of recombinant BTK enzyme and incubated for 30 minutes at room temperature. After the incubation, 40 nM Ultra light poly GT substrate mix from Perkin Elmer and 6 ⁇ ATP were added to the reaction and incubated for 30 min at room temperature. Reactions are quenched after 30 min by addition of 40 mM EDTA. After stopping the reaction, 0.5 nM of Eu-labelled antiphosphotyrosine antibody was added to the reaction.
  • the degree of phosphorylation of Ultra Light poly GT substrate was measured using a time -resolved fluorimeter (Perkin Elmer WALLAC 1420 Multi label Counter Victor 3) as ratio of specific 665 nm energy transfer signal to reference europium 615 nm signals.
  • the compounds IC 50 was determined by fitting the dose response data to sigmoidal curve fitting equation using GraphPad Prism software V5. The selected compounds were screened at ⁇ concentration and the results are summarized in table below.
  • IC 50 values of the selected compounds of present invention were provided in below table, Compounds exhibiting IC 50 values ⁇ 2.0 ⁇ were grouped as 'A' and the compounds exhibiting IC 50 value >2.0 ⁇ were grouped as 'B'.

Abstract

Cette invention concerne de nouveaux dérivés hétérocycliques N-substitués de formule (I) à titre d'inhibiteurs de protéines kinases, dans lesquels R1, R2 et 'n' ont les mêmes significations que celles indiquées dans la description, et des sels pharmaceutiquement acceptables de ceux-ci qui sont utiles pour traiter et prévenir des maladies ou des troubles, en particulier leur utilisation dans les maladies ou les troubles tirant profit de l'inhibition de l'enzyme kinase, plus particulièrement de l'enzyme BTK. Cette invention concerne en outre des procédés de synthèse et d'administration des composés inhibiteurs de kinases ainsi que des formulations pharmaceutiques comprenant au moins un des composés inhibiteurs de kinases selon l'invention avec un véhicule, un diluant ou un excipient pour celui-ci pharmaceutiquement acceptable.
PCT/IB2014/058894 2013-02-12 2014-02-11 Dérivés hétérocycliques n-substitués à titre d'inhibiteurs de kinases WO2014125410A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN599CH2013 2013-02-12
IN599/CHE/2013 2013-02-12

Publications (1)

Publication Number Publication Date
WO2014125410A1 true WO2014125410A1 (fr) 2014-08-21

Family

ID=51353539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058894 WO2014125410A1 (fr) 2013-02-12 2014-02-11 Dérivés hétérocycliques n-substitués à titre d'inhibiteurs de kinases

Country Status (1)

Country Link
WO (1) WO2014125410A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017128917A1 (fr) 2016-01-29 2017-08-03 北京诺诚健华医药科技有限公司 Dérivés de cycles condensés de parazole et procédé de préparation de ces derniers, et application de ces derniers dans le traitement de cancers, d'inflammation et de maladies immunitaires
CN113416181A (zh) * 2021-08-02 2021-09-21 四川大学 喹唑啉类衍生物及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053121A2 (fr) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
WO2006099075A2 (fr) * 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Amides substitues, procede pour les produire et procede pour les utiliser
WO2008033858A2 (fr) * 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Inhibiteurs de kinase et procédés d'utilisation et d'identification des inhibiteurs de kinase
WO2009039397A2 (fr) * 2007-09-20 2009-03-26 Cgi Pharmaceuticals, Inc. Amides substitués, procédé pour les préparer et procédé pour les utiliser
WO2009137596A1 (fr) * 2008-05-06 2009-11-12 Cgi Pharmaceuticals, Inc. Amides substitués, leur méthode de préparation et d'utilisation en tant qu'inhibiteurs de btk
WO2010000633A1 (fr) * 2008-07-02 2010-01-07 F. Hoffmann-La Roche Ag Nouvelles phénylpyrazinones en tant qu’inhibiteurs de kinases
WO2011140488A1 (fr) * 2010-05-07 2011-11-10 Gilead Connecticut, Inc. Composés de pyridone et d'aza-pyridone et leurs procédés d'utilisation
WO2012031004A1 (fr) * 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, leur procédé de fabrication et leur méthode d'utilisation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053121A2 (fr) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
WO2006099075A2 (fr) * 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Amides substitues, procede pour les produire et procede pour les utiliser
WO2008033858A2 (fr) * 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Inhibiteurs de kinase et procédés d'utilisation et d'identification des inhibiteurs de kinase
WO2009039397A2 (fr) * 2007-09-20 2009-03-26 Cgi Pharmaceuticals, Inc. Amides substitués, procédé pour les préparer et procédé pour les utiliser
WO2009137596A1 (fr) * 2008-05-06 2009-11-12 Cgi Pharmaceuticals, Inc. Amides substitués, leur méthode de préparation et d'utilisation en tant qu'inhibiteurs de btk
WO2010000633A1 (fr) * 2008-07-02 2010-01-07 F. Hoffmann-La Roche Ag Nouvelles phénylpyrazinones en tant qu’inhibiteurs de kinases
WO2011140488A1 (fr) * 2010-05-07 2011-11-10 Gilead Connecticut, Inc. Composés de pyridone et d'aza-pyridone et leurs procédés d'utilisation
WO2012031004A1 (fr) * 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, leur procédé de fabrication et leur méthode d'utilisation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017128917A1 (fr) 2016-01-29 2017-08-03 北京诺诚健华医药科技有限公司 Dérivés de cycles condensés de parazole et procédé de préparation de ces derniers, et application de ces derniers dans le traitement de cancers, d'inflammation et de maladies immunitaires
CN113416181A (zh) * 2021-08-02 2021-09-21 四川大学 喹唑啉类衍生物及其用途
CN113416181B (zh) * 2021-08-02 2022-05-03 四川大学 喹唑啉类衍生物及其用途

Similar Documents

Publication Publication Date Title
JP7191799B2 (ja) ピリミジン化合物及びその医薬用途
DK2953952T3 (en) MACROCYCLIC PYRIDAZININE DERIVATIVES
JP5560278B2 (ja) キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル
JP7094438B2 (ja) 大環状キナーゼ阻害剤
WO2018118842A1 (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
WO2014125408A2 (fr) Dérivés de 1h-pyrrolopyridinone substitués en tant qu'inhibiteurs de kinase
EA033698B1 (ru) Ингибиторы лизинспецифической деметилазы-1
EP2968339A1 (fr) Inhibiteurs mk2 et utilisations associées
JP2019500357A (ja) Ｂｔｋキナーゼ阻害剤の結晶形およびその製造方法
CA2654358A1 (fr) Derives de pyridine et de pyrazine utilises en tant qu'inhibiteurs de la kinase mnk
JP2013523756A (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
RU2636310C1 (ru) Новое тетерагидропиримидиновое соединение или его соль
AU2019209475A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP7369458B2 (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４－オキサジアゾール誘導体
KR20120034607A (ko) 이미다조〔2,1-ｂ〕〔1,3,4〕티아디아졸 유도체
WO2014155300A2 (fr) Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1
CN108495855B (zh) 作为mnk抑制剂的稠合噻唑并嘧啶衍生物
KR20120093428A (ko) 스핑고신 키나아제 저해제
WO2014106800A2 (fr) Dérivés de pyrimidine à substitution 2-amino servant de composés inhibiteurs de kinase
AU2020406824A1 (en) Novel pyrimidine derivative and use thereof
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
TW202317544A (zh) 吡啶酮mk2抑制劑及其用途
JP2022540671A (ja) サイクリン依存性キナーゼの阻害剤
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
EP2935272A1 (fr) Utilisation d'imidazopyrazines à substitution pyrazole comme inhibiteurs de caséine kinase 1 d/e

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14752020

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14752020

Country of ref document: EP

Kind code of ref document: A1